<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611047</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2021/60</org_study_id>
    <nct_id>NCT05611047</nct_id>
  </id_info>
  <brief_title>Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis</brief_title>
  <acronym>TELECOG-MS</acronym>
  <official_title>Multicentre Randomized Blinded Controlled Study of Specific Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis Using Mixed Evaluation and Ecological Validity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treating cognitive impairment (CI) in multiple sclerosis (MS), the leading cause of&#xD;
      disability due to nontraumatic neurological disease in young adults, is an important&#xD;
      challenge. The contribution of CI to disability in MS has been increasingly recognized, and&#xD;
      CI has been shown to decrease health-related quality of life (HR-QOL), even in the early&#xD;
      stages of the disease. CI negatively impacts daily activities such as driving, vocational&#xD;
      status, absenteeism, and instrumental activities in persons living with MS (PwMS). No&#xD;
      medication has proven to have a consistent symptomatic effect on CI in MS, and&#xD;
      disease-modifying therapies only have a small impact on CI progression.&#xD;
&#xD;
      CI in MS is dominated by a slowdown in information processing speed (IPS), as well as by&#xD;
      disturbances of more specific cognitive functions such as attention, episodic memory (EM),&#xD;
      working memory (WM) and executive function (EF). The alteration of IPS has consequences for&#xD;
      WM, attention, EF and EM. IPS impairment predicts subsequent disability and vocational status&#xD;
      and changes in quality of life (QOL).&#xD;
&#xD;
      Cognitive rehabilitation (CR) is the most promising approach for treating MS-related CI, as&#xD;
      concluded by recent reviews and meta-analyses, despite important methodological shortcomings.&#xD;
      Methodological limitations in early studies have led to disappointing results, and&#xD;
      well-designed studies are still scarce. As noted recently, many studies lack a randomized&#xD;
      controlled design that includes passive or active control conditions, primary&#xD;
      neuropsychological end-points identified a priori, evidence of the sustainability of CR and&#xD;
      the inclusion of near and far transfer outcomes. Tertiary outcomes of QOL, metacognition, or&#xD;
      other patient-reported outcomes (PROs) are rarely used.&#xD;
&#xD;
      In view of the results of these different studies, the investigators propose a single-blind&#xD;
      randomized controlled trial of a telerehabilitation program for MS associated CI, based on&#xD;
      Rehacom software, using appropriates modules according to specific CI, but complemented by&#xD;
      individual remote online rehabilitation sessions allowing a better adaptation of the program&#xD;
      to the patient's deficit, a more efficient supervision and meta-cognitive work. This program&#xD;
      will be evaluated in terms of effectiveness on neuropsychological tests, effectiveness on&#xD;
      specific cognitive domains re-educated according to the impairments detected in the baseline,&#xD;
      an ecological evaluation and the impact on daily cognitive functioning. Specific active&#xD;
      rehabilitation will be compared to a placebo intervention of the same duration and intensity.&#xD;
      Only a multi-center study will make it possible to achieve sufficient number of patients to&#xD;
      meet these objectives.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2023</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change of the four reaction time z scores over the 12 weeks of training in the ecological assessment of cognitive impairment (CI) using the Urban DailyCog®.</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the neuropsychological tests raw scores between baseline (W0) and after rehabilitation (W12) between the two groups</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the neuropsychological tests raw scores between visit W12 and visit W24 between the two groups.</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in information processing speed (IPS), composite z scores between W0-W12 and W12-W24</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in attention and working memory (WM) domain neuropsychological tests composite z scores and raw scores between W0-W12 and W12-W24 in subgroups of patients affected for these domains</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the sum of the 4 reaction time differences over the 12 weeks of training in the ecological assessment of CI using the Urban DailyCog®.</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the patient-reported outcomes (PROs) (depression anxiety) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the patient-reported outcomes (PROs) (daily cognitive functioning) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the patient-reported outcomes (PROs) (fatigue) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the patient-reported outcomes (PROs) (Health-Related Quality of Life) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between baseline (W0) and after rehabilitation (W12) between the two groups.</measure>
    <time_frame>12 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PROs (depression anxiety) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PROs (daily cognitive) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PROs (fatigue) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the PROs (Health-Related Quality of Life) and Subjective cognitive deficits questionnaire (PDQ and DCAQ) between W0 and the 24-weeks follow-up (W24) between the two groups.</measure>
    <time_frame>24 weeks after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Active cognitive rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham cognitive rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical assessment</intervention_name>
    <description>MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded</description>
    <arm_group_label>Active cognitive rehabilitation</arm_group_label>
    <arm_group_label>Sham cognitive rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Classical cognitive evaluation of several domains:</intervention_name>
    <description>Information processing speed (IPS) Working memory (WM) Executive functions (EF) Episodic memory (EM) Premorbid intelligence quotient (IQ) Multidomain or complex task</description>
    <arm_group_label>Active cognitive rehabilitation</arm_group_label>
    <arm_group_label>Sham cognitive rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ecological evaluation</intervention_name>
    <description>Virtual reality task : Urban DailyCog©</description>
    <arm_group_label>Active cognitive rehabilitation</arm_group_label>
    <arm_group_label>Sham cognitive rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Patent reported outcomes (PRO's)</intervention_name>
    <description>Patent reported outcomes (PRO's) : Beck Depression Inventory (BDI), European Quality of Life-5 Dimensions (EQ-5D-5L) for Health-Related Quality of Life (HRQOL), Multiple Sclerosis Impact Scale-29 Items (MSIS-29), French version of the Modified Fatigue Impact Scale (EMISEP) and State trait anxiety inventory (STAI).&#xD;
Subjective cognitive deficits: Perceived Deficits Questionnaire (PDQ) and Cognitive Activities Questionnaire (DCAQ)</description>
    <arm_group_label>Active cognitive rehabilitation</arm_group_label>
    <arm_group_label>Sham cognitive rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telerehabilitation : active procedure</intervention_name>
    <description>The Cognitive rehabilitation (CR) consists of weekly 45 minutes online individual session with the unblinded Speech Therapist.</description>
    <arm_group_label>Active cognitive rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telerehabilitation : comparator procedure</intervention_name>
    <description>Once per week over a 12-week period completed by daily online exercises performed by the patient 4 days a week.</description>
    <arm_group_label>Sham cognitive rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  Age 18-55 years;&#xD;
&#xD;
          -  Native French speaking;&#xD;
&#xD;
          -  Definite diagnosis of Relapsing-remitting MS (RRMS) according to McDonald 2017&#xD;
             criteria;&#xD;
&#xD;
          -  Disease duration&gt; 12 months and ≤ 15 years;&#xD;
&#xD;
          -  Computerized-Screening Cognitive Test (CSCT) score ≤ - 1.282 Standard Deviations (SD)&#xD;
             (10th percentile) and/or cognitive complaint;&#xD;
&#xD;
          -  2 scores &lt; -1.5 SD et &gt; -3.0 SD for 4 tests of the neuropsychological baseline battery&#xD;
             in one of the following domains: VTI or WM or attention (divided Attention, selective&#xD;
             attention and working memory subtest of the WAIS IV);&#xD;
&#xD;
          -  Able to use a computer, an internet connection;&#xD;
&#xD;
          -  Being affiliated to health insurance&#xD;
&#xD;
          -  Having signed an informed consent (at the latest on the day of inclusion and before&#xD;
             any examination required by research)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of other neurological disease;&#xD;
&#xD;
          -  Psychiatric comorbidity including severe depression according to Diagnostic and&#xD;
             Statistical Manual-IV (DSM-IV);&#xD;
&#xD;
          -  Current dependence on alcohol or other addiction to toxic;&#xD;
&#xD;
          -  Disabling visual or motor problems preventing participation to neuropsychological&#xD;
             assessments;&#xD;
&#xD;
          -  Change of psychotropic drug or disease-modifying therapies since less than one month;&#xD;
&#xD;
          -  Illiteracy, ie: unable to count or to read;&#xD;
&#xD;
          -  Acquisition disorders: dyslexia, dysphasia, dyscalculia and dyspraxia;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty&#xD;
             by a judicial or administrative decision, minors, persons of legal age who are the&#xD;
             object of a legal protection measure or unable to express their consent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie RUET, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie RUET, Prof</last_name>
    <phone>05 56 79 55 21</phone>
    <phone_ext>+33</phone_ext>
    <email>aurelie.ruet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde DELOIRE, PhD</last_name>
    <phone>05 57 82 12 75</phone>
    <phone_ext>+33</phone_ext>
    <email>mathilde.deloire@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - Service de neurologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie RUET, Prof</last_name>
      <phone>05 56 79 55 21</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.ruet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde DELOIRE, PhD</last_name>
      <phone>05 57 82 12 75</phone>
      <phone_ext>+33</phone_ext>
      <email>mathilde.deloire@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand - Service de neurologie</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre CLAVELOU, Prof</last_name>
      <email>pclavelou@chu-clermont-ferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre CLAVELOU, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon-Bourgogne - Service de neurologie</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thibault MOREAU, Prof</last_name>
      <email>thibault.moreau@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Thibault MOREAU, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Dunkerque - Service de neurologie</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Bertin NKENDJUO, MD</last_name>
      <email>Jean-Bertin.Nkendjuo@ch-dunkerque.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Bertin NKENDJUO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul - Service de neurologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud KWIATKOWSKI, MD</last_name>
      <email>kwiatkowski.arnaud@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Arnaud KWIATKOWSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Service de neurologie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier AYRIGNAC, MD</last_name>
      <email>xavier.ayrignac@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier AYRIGNAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Hôpital de Poissy Saint Germain en Laye - Service de neurologie</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier HEINZLEF, MD</last_name>
      <email>oheinzlef@chi-poissy-st-germain.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier HEINZLEF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>August 30, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>March 13, 2023</last_update_submitted>
  <last_update_submitted_qc>March 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Diseases of the Nervous System</keyword>
  <keyword>Demyelinating Autoimmune Diseases</keyword>
  <keyword>Demyelinating Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>ecological assessment</keyword>
  <keyword>telerehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

